Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tanruprubart - Annexon

Next Previous
Drug Profile

Tanruprubart - Annexon

Alternative Names: ANX 005

Latest Information Update: 30 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Annexon
  • Class Antianaemics; Monoclonal antibodies
  • Mechanism of Action Complement C1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Guillain-Barre syndrome; Huntington's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Guillain-Barre syndrome
  • Phase II Amyotrophic lateral sclerosis; Autoimmune haemolytic anaemia; Huntington's disease
  • No development reported Autoimmune disorders; Neurodegenerative disorders

Most Recent Events

  • 19 May 2025 Updated efficacy data from a phase-III trial in Guillain-Barre syndrome released by Annexon
  • 12 May 2025 Annexon plans the phase III FORWARD trial for Guillain-Barre syndrome (In children, In adolescents, In adults, In the elderly) in USA, Canada and Europe (IV, infusion) in June 2025 (NCT07020819)
  • 08 Apr 2025 Updated efficacy and adverse event data from phase III trial in Guillain-Barre syndrome released by Annexon

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top